Connect Biopharma Holdings Stock
Connect Biopharma Holdings Limited
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Barry D. Quart
- Employees
- 64
- Market cap
- $57 M
- IPO
- 19/03/2021
Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical company dedicated to discovering and advancing immune modulators. Its primary objective is to develop treatments for serious autoimmune diseases and various inflammatory conditions. The company's lead investigational therapy is CBP-201, an…
Connect Biopharma Holdings stock: price history
1D
+0.0%
1W
+4.2%
1M
-26.9%
6M
-67.7%
YTD
-67.9%
1Y
-50.5%
2Y
-27.5%
5Y
-94.7%
10Y
–
Next earnings date
Next earnings date
11/11/2026 (in 25 days)
Volatility around earnings
~3% stronger price swings than usual
Ask the agents about Connect Biopharma Holdings
Analyst assessment of Connect Biopharma Holdings
PRICE TARGET LOW
US$4.00
CONSENSUS
US$6.60
MEDIAN
US$7.00
PRICE TARGET HIGH
US$8.00
0
STRONG BUY
7
BUY
0
HOLD
0
SELL
0
STRONG SELL
7
TOTAL · Buy
As of: 08/10/2026
Connect Biopharma Holdings stock metrics
P/E
-1.03
P/B
2.12
EV/EBITDA
-0.59
RETURN ON EQUITY
-136.6%
NET MARGIN
-1,249.0%
DEBT/EQUITY
0.02
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
26.2%
FLOAT SHARES
16,501,534
AVG. DAILY VOLUME (30D)
7,595,756
Insider transactions (SEC)
LIU JEAN I
Xanthopoulos Kleanthis Gabriel
LIU JEAN I
Xanthopoulos Kleanthis Gabriel
Huang James
Institutional holders
Comparable stocks
Frequently asked questions about Connect Biopharma Holdings stock
What does Connect Biopharma Holdings do?
Connect Biopharma Holdings Limited is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Barry D. Quart, the company employs around 64 people.
The IPO was on 19/03/2021; the stock trades on NASDAQ under the ticker CNTB.
What do analysts say about Connect Biopharma Holdings stock?
7 analysts rate the stock, the consensus is Buy (as of 08/10/2026).
The average price target is US$6.60, ranging from US$4.00 to US$8.00, with a median of US$7.00.
This is an external assessment, not a statement by Market Jury.
When does Connect Biopharma Holdings report next?
The next earnings date is 11/11/2026.
Around past earnings, price swings were roughly 3% stronger than usual.
Does Connect Biopharma Holdings pay a dividend?
No, Connect Biopharma Holdings currently does not pay a dividend.
Which stocks are comparable to Connect Biopharma Holdings?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Connect Biopharma Holdings stock analyzed?
Clicking "Analyze stock" lets five strategies assess Connect Biopharma Holdings against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.